Induced mild hypothermia: 

In order to improve the outcome of post cardiac arrest patients the latest European Resuscitation Council recommends that all such patients (contraindication patients excluded) are subject to therapeutic hypothermia. The teraphy is based on a controlled temperature reduction. The main goal of the teraphy is the reduction of neurological complications that are often seen in this group of patients. Hypothermia's efficiency is described as high. Out of 6 patiens 1 will benefit clinically from the teraphy (NNT=6). Hypothermia recommendations: 

Out-of-hospital cardiac arrest in VF mechanism:  

ERC           ILCOR             American Heart Association

( I / B )         ( I / B )                      ( I / B ) 

Out-of-hospital cardiac arrest in asystolic mechanism or PEA

 ERC           ILCOR             American Heart Association

( IIb / C)       ( IIa / B )                    ( I / B )

We offer a complete solution for the mild therapeutic hypothermia. It is called Blanketrol III, and allows for cooling the patient down and maintaining the programmed temperature usually 32OC-34OC for 12 to 24 hours. Hypothermia appears to limit damage to the brain cells by decreasing cerebral oxygen demand and reducing the brain’s metabolic activity. The system allows for the full patient's temperature control which means that it allows also for controlled rewarming. The system is reliable and cost effective due to a wide range of accessories.

Since June 2012 Medicavera is a technological partner of Polish Hypothermia Register.